APOC1 and Miyoshi myopathy: Moreover, analysis of BTZ-induced systemic changes via proteomic profiling of sera from RRMM patients revealed elevated levels of apolipoprotein C1 (ApoC1), quiescin sulfhydryl oxidase 1 (QSOX1) and complement components in MM patients with lower response rates towards BTZ-containing regimens.